Heron Therapeutics, Inc. (NASDAQ:HRTX) recovered 9.32% of its value since hitting low of $16.2. The recent move of 3.39% gain helped the stock to close at $17.71 when trading ended on 6/7/2019. At a recent session, the prices were hovering between $17.095 and $17.83. This company shares are 144.33% off its target price of $43.27 and the current market capitalization stands at $1.36B. The recent change has given its price a -15.08% deficit over SMA 50 and -58.72% deficit over its 52-week high. The stock witnessed 4.61% gains, -31.2% declines and -36.48% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found HRTX’s volatility during a week at 3.81% and during a month it has been found around 4.09%.Heron Therapeutics, Inc. (HRTX) Top Holders
Institutional investors currently hold around $1.64 billion or 0% in HRTX stock. Look at its top three institutional owners: Franklin Resources Inc owns $151.93 million in Heron Therapeutics, Inc., which represents roughly 11.17% of the company’s market cap and approximately 9.25% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 8,473,847 shares of the stock are valued at $150.07 million. The third largest holder is Vanguard Group Inc, which currently holds $113.6 million worth of this stock and that ownership represents nearly 8.35% of its market capitalization.
At the end of March reporting period, 111 institutional holders increased their position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by some 9,818,751 shares, 67 decreased positions by 7,933,157 and 34 held positions by 74,995,388. That puts total institutional holdings at 92,747,296 shares, according to SEC filings. The stock grabbed 35 new institutional investments totaling 2,357,331 shares while 14 institutional investors sold out their entire positions totaling 661,025 shares.Heron Therapeutics, Inc. (NASDAQ:HRTX) Insider Trades
Multiple company employees have indulged in significant insider trading. Heron Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director POYHONEN JOHN has acquired 3,000 shares of Heron Therapeutics, Inc. (HRTX) in the trading session dated May. 22, 2019. These shares are worth $52,650 and were traded at $17.55 each. The SEC filing shows that Christian Waage performed a purchase of 1,400 shares. The Director added these shares by way of transaction on May. 15, 2019. The company’s shares were assimilated at $18.04 per share worth to an investment of some $25,256 to the account of Christian Waage.
Executive VP, Drug Development, MANHARD KIMBERLY, sold 1,109 common shares of Heron Therapeutics, Inc. (HRTX) in the open market. In a transaction dated May. 01, 2019, the shares were put up for sale at an average price of $18.86, raking in a sum of $20,916. After this sale, common shares of HRTX are directly owned by the insider, with total stake valued at $.
In the transaction dated Nov. 02, 2018, a great number of shares sold came courtesy the Executive VP, Drug Development; MANHARD KIMBERLY disposed a total of 494 shares at an average price of $30.62, amounting to approximately $15,126. The insider now directly owns shares worth $.
Several analysts have released their opinion on Heron Therapeutics, Inc. (NASDAQ:HRTX), with 6 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.45 average brokerage recommendation [T1].